Skip to main
LIVN
LIVN logo

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova's sales experienced robust growth, boasting a 29% increase to $803 million in 2024, with management projecting continued growth through guidance of $940-955 million for the upcoming year. The company's focus on expanding the aura6000's market share is evident, with optimistic projections in the Bull Case scenario estimating sales of $120 million in 2027 and $280 million by 2029 as the market share grows from 9.0% to 14.9%. With significant revenue streams originating from both the US market and Europe, LivaNova's strategic positioning in cardiopulmonary solutions and neuromodulation devices suggests a strong potential for future revenue growth.

Bears say

LivaNova's financial outlook is negatively affected by anticipated revenue growth slowing to the low-single digits due to persistent challenges in its Neuromodulation and Cardiovascular sectors, coupled with operating margin contraction. The company faces significant risks, including the potential failure to secure FDA approval for the aura6000 device, which could hinder Neuromodulation and Cardiopulmonary growth and result in weaker-than-expected margin improvements. Overall, these factors contribute to a bearish scenario, with forecasts of below-consensus earnings further compounding the company's financial struggles.

Livanova (LIVN) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 7 analysts, Livanova (LIVN) has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.